SCHEMBL15859005

SCHEMBL15859005

COc1cncc(C)c1OC

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 1/20 0.41
MAOA P21397 2/20 0.36
AGXT P21549 1/20 0.36
ALDH1A1 P00352 3/20 0.34
CYP3A4 P08684 1/20 0.34
MAPT P10636 1/20 0.34
CA9 Q16790 1/20 0.34
BRAF P15056 4/20 0.34
CYP11B1 P15538 1/20 0.33
CYP11B2 P19099 1/20 0.33
BRD4 O60885 1/20 0.33
KDM4E B2RXH2 2/20 0.33
LMNA P02545 1/20 0.33
TP53 P04637 1/20 0.33
HIF1A Q16665 1/20 0.33
TUBB1 Q9H4B7 3/20 0.33
TUBB4A P04350 2/20 0.33
TUBB P07437 2/20 0.33
TUBA3C P0DPH7 2/20 0.33
TUBA1B P68363 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4396043 0.85 ACHE (0.48) ACHEMAOAALDH1A1CYP3A4MAPT
SCHEMBL3447464 0.85 AGXT (0.41) ACHEMAOAAGXTALDH1A1BRAF
Hydrochloric Acid SCHEMBL17591666 0.82 AGXT (0.39) ACHEMAOAAGXTALDH1A1BRAF
SCHEMBL29682842 0.82 AGXT (0.39) ACHEMAOAAGXTALDH1A1BRAF
SCHEMBL17485540 0.78 ALDH1A1 (0.36) ACHEALDH1A1MAPTCA9
SCHEMBL22454477 0.76 PDE4D (0.38) ACHEAGXTALDH1A1CYP11B1CYP11B2
SCHEMBL24108644 0.74 ALDH1A1 (0.34) ACHEALDH1A1CYP3A4MAPTCA9
SCHEMBL21736978 0.74 ALDH1A1 (0.38) ALDH1A1CYP11B1CYP11B2KDM4E
SCHEMBL13724673 0.74 CA2 (0.37) ACHEAGXTCYP11B1CYP11B2
SCHEMBL24899923 0.74 AGXT (0.35) ACHEAGXTCYP11B1CYP11B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021127328-A1 TRPML MODULATORS CASMA THERAPEUTICS, INC. (US) 2021-06-24 WO disclosed
WO-2021127337-A1 TRPML MODULATORS CASMA THERAPEUTICS, INC. (US) 2021-06-24 WO disclosed
WO-2021127333-A1 TRPML MODULATORS CASMA THERAPEUTICS, INC. (US) 2021-06-24 WO disclosed
US-9676780-B2 Piperazine-substituted [1,2,4]triazolo[1,5-C]quinazolin-5-amine compounds with A2A antagonist properties MERCK SHARP & DOHME CORP. (US) 2017-06-13 US disclosed
US-20160194330-A1 PIPERAZINE-SUBSTITUTED [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES MERCK SHARP & DOHME CORP. (US) 2016-07-07 US disclosed
WO-2014101113-A1 PIPERAZINE-SUBSTITUTED 7-METHOXY-[1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES MERCK SHARP & DOHME CORP. (US) 2014-07-03 WO disclosed
CN-85104684-A The dialkoxy pyridine, their preparation method, purposes and contain their medicine 1986-12-31 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160194330-A1 PIPERAZINE-SUBSTITUTED [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES ADORA2A, ADORA1, ADORA3 ACHE 362/4885MAOA 243/4885AGXT 2730/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.